COMP <GO>
PCVX vs KYMR // NET PROFIT MARGIN
Vaxcyte Inc. (NASDAQ) VS. Kymera Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PCVX 4
— KYMR 6
▲ NET PROFIT MARGIN LEADER: KYMR
LAST: $62.03 (-0.93%) • MKT CAP: $9.76B
net-margins
0.00%
LAST: $126.63 (+3.29%) • MKT CAP: $10.81B
net-margins
68.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. KYMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | KYMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | -21.40% | -6.20 | KYMR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | -2.30% | -4.49 | KYMR | /fcf-yield <GO> |
| Operating Margin | -33.50% | -60.00% | +26.50 | PCVX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 0.00% | 68.00% | -68.00 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | 19.80% | -16.70% | +36.50 | PCVX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 26.00 | -7.89 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 66.0 | -17.30 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.95 | +0.12 | PCVX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 30.4x | -7.40 | PCVX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.76B | $10.81B | -$1.05B | KYMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | KYMR REV | PCVX GROSS % | KYMR GROSS % | PCVX FCF | KYMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $39.2M | — | 0.0% | -$669.3M | -$234.3M |
| FY 2024 | $0 | $47.1M | — | 0.0% | -$475.1M | -$207.3M |
| FY 2023 | $0 | $78.6M | — | — | -$296.8M | -$106.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
KYMR // BETA 0.95